Analysts' Actions -- General Mills, MasterCard, Visa, Valeant and More

RATINGS CHANGES 

Comerica (CMA) was upgraded to neutral from underperform at Bank of America/Merrill Lynch. $70 price target. The company has strong earnings leverage to higher interest rates, analysts said. 

Brinker (EAT) was downgraded to underperform at BMO Capital. The valuation is less attractive, based on a $45 price target. 

Flowers Foods (FLO) was upgraded to equal-weight from sector weight at Keybanc. $23 price target. Expect more settlements and cost-cutting efforts from the company, Keybanc said. 

General Mills (GIS)  was downgraded to sector perform from outperform at RBC Capital. $69 price target. Earnings estimates were also cut, given accelerating volume declines, RBC said. 

Heico (HEI) was upgraded to outperform from neutral at Credit Suisse. $86 price target. The company generates consistent free-cash flow, which should be augmented by recent acquisitions, Credit Suisse said. 

Halyard (HYH) was downgraded to hold from buy at Deutsche Bank. $35 price target. 2017 will likely be another transitional year, Deutsche said. 

Instructure (INST) was initiated as a sell at TheStreet Ratings. You can view the full analysis from the report here: INST.

MasterCard (MA) was upgraded to buy at Bank of America/Merrill Lynch. $120 price target. The company is a consistent grower and deserves a premium valuation, analysts said. 

M&T Bank (MBT) was downgraded to underperform from neutral at Bank of America/Merrill Lynch. $155 price target. The company has limited relative earnings upside potential, analysts said. 

Stifel Financial (SF) was upgraded to buy at TheStreet Ratings. You can view the full analysis from the report here: SF.

Swift (SWFT) was upgraded to overweight from neutral at J.P. Morgan. $31 price target. The company is leveraged to a turn in the truckload cycle, J.P. Morgan said. 

Univar (UNVR) was upgraded to outperform from market perform at Wells Fargo. The company can improve execution, despite a muted sales environment, Wells said. 

Visa (V) was upgraded to buy at Bank of America/Merrill Lynch. $92 price target. The company can deliver consistent growth and deserves a premium valuation, analysts said. 

Valeant Pharmaceuticals (VRX) was downgraded to equal-weight from overweight at Morgan Stanley. $17 price target. Earnings estimates were also cut, given weaker business trends, Morgan said. 

This article was written by a staff member of TheStreet.

More from Stocks

Biotech's Coming Back to Life: Cramer's 'Off the Charts'

Biotech's Coming Back to Life: Cramer's 'Off the Charts'

Video: Here's How Goldman Sachs May Change Under David Solomon

Video: Here's How Goldman Sachs May Change Under David Solomon

J&J Vows to Fight Verdict Linking Baby Powder to Ovarian Cancer

J&J Vows to Fight Verdict Linking Baby Powder to Ovarian Cancer

3 Reasons Why Netflix Bulls Are Getting Their Face Ripped Off After Earnings

3 Reasons Why Netflix Bulls Are Getting Their Face Ripped Off After Earnings

Markets Close Higher After Fed Chair Powell's Capitol Hill Testimony

Markets Close Higher After Fed Chair Powell's Capitol Hill Testimony